Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS

References

• Mathioudakis AG, Vestbo J, Singh D. Long-acting bronchodilators for chronic obstructive pulmonary disease: which one(S), how, and when? Clin Chest Med. 2020;41(3):463–474. PMID: 32800199. doi:10.1016/j.ccm.2020.05.005
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global initiative for chronic obstructive lung disease global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2023. Available from: http://www.goldcopd.org/. Accessed July 14, 2023.
   Google Scholar
• Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010;137(2):318. doi:10.1378/chest.09-1305
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297. doi:10.1136/bmj.320.7245.1297
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest. 2006;130(3):640. doi:10.1378/chest.130.3.640
   PubMed Web of Science ®Google Scholar
• Wise R, Connett J, Weinman G, Scanlon P, Skeans M; Lung health study research group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902.
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991. doi:10.1002/14651858.CD002991.pub3
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. 2012 Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829. PMID: 22972099; PMCID: PMC4170910. doi:10.1002/14651858.CD006829.pub2
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, Kesterton A. 2013 Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;30(8):CD006826. PMID: 23990350; PMCID: PMC6486274. doi:10.1002/14651858.CD006826.pub2
   Google Scholar
• Singh D, Agusti A, Martinez FJ, et al. Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 review. Am J Respir Crit Care Med. 2022;206(1):17–24. doi:10.1164/rccm.202201-0209PP
   PubMed Web of Science ®Google Scholar
• NICE Guideline Updates Team (UK). Inhaled Triple Therapy: Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management: Evidence Review I PMID: 32755138. London: National Institute for Health and Care Excellence (UK); 2019.
   Google Scholar
• Papi A, Petruzzelli S, Vezzoli S, Georges G, Fabbri LM. Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations. Eur Respir J. 2019;53(4):1900147. PMID: 31000665. doi:10.1183/13993003.00147-2019
   PubMedGoogle Scholar
• Barnes PJ. Scientific rationale for inhaled combination with long acting β2-agonisitslong-acting β 2 -agonists and corticosteroids. Eur Respir J. 2002;19(1):182. doi:10.1183/09031936.02.00283202
   PubMed Web of Science ®Google Scholar
• Haque R, Hakim A, Moodley T, et al. Inhaled long acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol. 2013;132(5):1166. doi:10.1016/j.jaci.2013.07.038
   PubMed Web of Science ®Google Scholar
• Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172(6):704. doi:10.1164/rccm.200408-1041OC
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34. doi:10.1513/AnnalsATS.201409-413OC
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gupta E, Scanlon PD. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD. 2016;13(3):312. doi:10.3109/15412555.2015.1081162
   PubMedGoogle Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: arctic an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Latorre M, Novelli F, Vagaggini B, et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS. Pulm Pharmacol Ther. 2015;30:44. doi:10.1016/j.pupt.2014.10.006
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Rigby A, Morice AH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung. 2017;195(3):281. doi:10.1007/s00408-017-9990-8
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029. doi:10.1136/thoraxjnl-2012-202872
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Carratalà J, Fernández-Sabé N, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15(11):1033. doi:10.1111/j.1469-0691.2009.02918.x
   PubMed Web of Science ®Google Scholar
• Molinos L, Clemente MG, Miranda B, et al.; for the ASTURPAR group. Community-acquired pneumonia in patient with and without chronic obstructive pulmonary disease. J Infect. 2009;58(6):417. doi:10.1016/j.jinf.2009.03.003
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641. doi:10.1183/09031936.00193908
   PubMed Web of Science ®Google Scholar
• Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 2009;103(2):224. doi:10.1016/j.rmed.2008.09.005
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219. doi:10.1183/13993003.01219-2018
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346(may29 4):f3306. doi:10.1136/bmj.f3306
   PubMedGoogle Scholar
• Chang TY, Chien JY, Wu CH, Dong YH, Lin FJ. Comparative safety and effectiveness of inhaled corticosteroid and long acting β2 agonist combination in patients with COPD. Chest. 2020;157(5):1117. doi:10.1016/j.chest.2019.12.006
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li S, Zhou W, Yang X, Li J, Cao J. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020;17(4):462. doi:10.1080/15412555.2020.1787369
   PubMedGoogle Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al.; for the FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Resp Med. 2014;108(8):1153. doi:10.1016/j.rmed.2014.05.013
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al.; for the IMPACT Investigators. Once-daily single inhaler triple versus dual therapy in patient with COPD. N Engl J Med. 2018;378(18):1671. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Sonnappa S, Martin R, Israel E, et al.; Respiratory Effectiveness Group, Small Airways Study Group. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017;12(6):e0178112. doi:10.1371/journal.pone.0178112
   PubMed Web of Science ®Google Scholar
• Price DB, Henley W, Cançado JED, et al. Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone. Int J Chron Obstruct Pulmon Dis. 2022;17:355–370. doi:10.2147/COPD.S342357
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multi Behav Res. 2011;46(3):399. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• R Core Team. 2020. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: https://www.R-project.org/. Accessed December 28, 2023.
   Google Scholar
• Wise RA, Bafadhel M, Crim C, et al. Discordant diagnostic criteria for pneumonia in COPD trials: a review. Eur Respir Rev. 2021;30(162):210124. doi:10.1183/16000617.0124-2021
   PubMed Web of Science ®Google Scholar
• Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042. doi:10.1183/09031936.00074905
   PubMed Web of Science ®Google Scholar
• Lipworth B, Kuo CR, Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3003. doi:10.2147/COPD.S177333
   PubMed Web of Science ®Google Scholar
• Thomsen M, Nordestgaard BG, Vestbo J, Lange P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med. 2013;1(7):543. doi:10.1016/S2213-2600(13)70137-1
   PubMed Web of Science ®Google Scholar